Eleni Efstathiou, MD, PhD

Experts offer concluding remarks on castration-sensitive prostate cancer, sharing their perspectives on the evolving field and expressing their aspirations for future advancements in disease treatment.

Key opinion leaders outline a case study of a patient with metastatic castration-sensitive prostate cancer, detailing the chosen treatment approaches and the overall outcome of the case.

Experts present a case study of a patient with non-metastatic castration-sensitive prostate cancer exhibiting rapid PSA doubling, highlighting the clinical implications and potential treatment considerations.

Specialists examine non-metastatic castration-sensitive prostate cancer cases, evaluating the significance of PSA doubling time and the reliability of biomarkers in risk assessment for these patients.

Prostate cancer experts analyze the EMBARK trial, emphasizing the potential impact of an androgen receptor inhibitor in the treatment of non-metastatic castration-sensitive prostate cancer.

Key opinion leaders examine the treatment landscape for castration-sensitive prostate cancer, highlighting prevalent first-line approaches and discussing the role of androgen deprivation therapy in the treatment paradigm.

The panel of prostate cancer experts explores risk stratification methodologies and prognostic markers for castration-sensitive prostate cancer, emphasizing crucial factors that influence patient categorization and treatment decisions.

Key opinion leaders examine the principles and advantages of early intervention strategies for patients with castration-sensitive prostate cancer.

Summarizes the main points and benefits of multidisciplinary prostate cancer care.

Covers key factors in deciding on radiation treatment.

Discusses treatment options for advanced metastatic disease.

Looks at approaches for isolated lymph node involvement.

Examines the considerations for operating on older prostate cancer patients.

Reviews a case of a patient with high PSA but no other symptoms.

Explains the importance of respect and collaboration between care providers.

Focuses on patients being active participants in their treatment choices.

Highlights the advantages of various providers working together for patient care.

Panel discusses how collaboration between specialties improves patient outcomes.

Brief background on prostate cancer and overview of the program.

Eleni Efstathiou, MD, PhD, discusses second interim findings from a subgroup analysis of the phase 3 MAGNITUDE trial in patients with BRCA-mutated metastatic castration-resistant prostate cancer.